Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Equity Average (2016 - 2025)

Historic Equity Average for Protalix BioTherapeutics (PLX) over the last 16 years, with Q3 2025 value amounting to $51.4 million.

  • Protalix BioTherapeutics' Equity Average rose 6849.29% to $51.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.4 million, marking a year-over-year increase of 6849.29%. This contributed to the annual value of $38.4 million for FY2024, which is 23485.98% up from last year.
  • Per Protalix BioTherapeutics' latest filing, its Equity Average stood at $51.4 million for Q3 2025, which was up 6849.29% from $47.6 million recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Equity Average registered a high of $51.4 million during Q3 2025, and its lowest value of -$11.1 million during Q4 2022.
  • Moreover, its 5-year median value for Equity Average was $20.0 million (2023), whereas its average is $17.2 million.
  • Its Equity Average has fluctuated over the past 5 years, first plummeted by 62794.77% in 2022, then soared by 75775.54% in 2024.
  • Over the past 5 years, Protalix BioTherapeutics' Equity Average (Quarter) stood at -$2.9 million in 2021, then plummeted by 280.46% to -$11.1 million in 2022, then surged by 424.17% to $35.9 million in 2023, then increased by 5.34% to $37.8 million in 2024, then soared by 35.91% to $51.4 million in 2025.
  • Its last three reported values are $51.4 million in Q3 2025, $47.6 million for Q2 2025, and $44.2 million during Q1 2025.